Currently Viewing:
Newsroom
Currently Reading
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff
Study Finds Breathing Retraining Associated With Quality of Life Improvement for Patients With Asthma
December 14, 2017 – Laura Joszt
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro

WHO Taps Into Biosimilars for Access to Expensive Cancer Drugs in Poor Nations

Surabhi Dangi-Garimella, PhD
The World Health Organization (WHO) has announced a pilot project that will take advantage of expected savings from biosimilar medications, particularly expensive anticancer agents, to make these treatments available for low- and middle-income countries.
The World Health Organization (WHO) has announced a pilot project that will take advantage of expected savings from biosimilar medications, particularly expensive anticancer agents, to make these treatments available for low- and middle-income countries.

The agency plans to focus on 2 anticancer drugs, rituximab and trastuzumab, which are included in the WHO Essential Medicines List. This list includes medicines that “satisfy the priority care needs of the population,” and candidate medications are selected based on disease prevalence and evidence of safety, efficacy, and drug cost as well as cost effectiveness.

For the pilot project, WHO will invite manufacturers of biosimilar products to submit applications for prequalification of their biosimilar versions of rituximab and trastuzumab. Rituximab is primarily indicated for non-Hodgkin's lymphoma and chronic lymphocytic leukemia, while trastuzumab is indicated for breast cancer. There might also be a similar project for prequalifying insulin. Prequalification by WHO can also increase market competition and further reduce drug price.

WHO invited national regulators, pharmaceutical industry groups, patient and civil society groups, payers, and policymakers to participate in a 2-day meeting in Geneva to address ways to increase access to costly biologic medications. “Innovator biotherapeutic products are often too expensive for many countries, so biosimilars are a good opportunity to expand access and support countries to regulate and use these medicines,” said Marie-Paule Kieny, MD, WHO assistant director general for health systems and innovation.

Biosimilars submitted for prequalification, if found comparable to the reference product with respect to quality, safety, and efficacy, will be listed by WHO, thereby making them eligible for procurement by the United Nations agencies. With regard for safety and efficacy for biosimilar products, WHO will evaluate countries that have had a positive experience with biosimilars and it plans to educate both patients and providers on the benefit of these medicines.

With respect to the economics of biosimilars, WHO plans to lend support to countries to develop price-setting strategies that can save money for patients and payers, while maintaining incentives for manufacturers.

A biosimilar to trastuzumab, manufactured by Biocon and Mylan, recently received marketing approval in India for additional indications of early-stage breast cancer and gastric cancer. The product is currently under review with both the FDA and the European Medicines Agency. Additionally, the South Korean company Celltrion has announced US regulatory filings for its biosimilar versions of both trastuzumab and rituximab.

  

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!